公司資料
MDxHealth 股價、新聞與催化劑
- 股票代碼:
- MDXH
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- Belgium and listed in the U
股票表現
0.86 USD (+5.89%)
收盤價
最後更新: 2026年8月17日
32.9M USD
市值
股價為何變動
As of Aug 17, 2026, MDXH closed up 5.89% at $0.8556. No new same-company headline was identified in the current news window.
公司概覽
Precision Urologic Diagnostics
MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.
Prostate Cancer Menu
The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic, epigenomic, and exosomal technologies.
ExoDx Integration
The acquired ExoDx urine-based prostate test broadens the diagnostic menu and is being integrated into MDxHealth’s laboratory, sales, and reimbursement infrastructure.
Portfolio Refocus
MDxHealth is exiting the Resolve UTI business to concentrate investment on prostate cancer and related urologic oncology opportunities.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。